Skip to main content
Discovering the causes of cancer and the means of prevention
 

Predictors of Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT)

Donor IFNL4-null Genotype Improved Survival in HSCT Recipients with Acute Leukemia

Shahinaz Gadalla and Ludmila Prokunina-Olsson analyzed data on more than 1500 recipient-donor pairs from the Center for International Blood and Marrow Transplant Research repository and database.

Allogeneic hematopoietic cell transplant (HCT) is the treatment of choice for many severe life-threatening malignant or non-malignant diseases of the hematopoietic system. Despite significant improvement in survival after HCT, patient still suffer high mortality and morbidity risk from disease relapse or transplant-related complications.  

Studies in the Clinical Genetics Branch aim to improve patient survival by identifying biomarkers that can guide donor selection or refine patient risk stratification. Ongoing research includes patients receiving HCT for severe aplastic anemia or myeloid neoplasms.  

For more information, contact  Shahinaz Gadalla. 

Clinical Genetics Branch - Research Areas 

 

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Predictors of Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT) was originally published by the National Cancer Institute.”